|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical tableaux of high suspicion of neuroendocrine cancer included radiological progression of a metastatic disease without PSA rise, relatively extended metastatic disease associated to a low PSA, disease with non-pulmonary visceral metastases.
|
31414399 |
2019 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Serum PSA was significantly negatively correlated with serum total oxidant status (<i>r</i>= -0.309, <i>p</i> = .003) but there was no significant correlation between PSA and 25(OH)D (<i>p</i> = .383) or total antioxidant levels (<i>p</i> = .233).
|
30084276 |
2019 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AR expression also correlated with downstream targets PSA (KLK3) and PSMA (FOLH1) and increased cell proliferation.
|
29249638 |
2018 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On multivariate analysis, only higher values of PSA significantly affected the odds of extensive LNI when compared to cases without (odds ratio, 1.054; p = .005); PSA showed a fair discrimination power (area under the curve 0.792).
|
29714659 |
2018 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While an elevated PSA significantly increases the risk of men harboring prostate cancer, many men with a persistently elevated PSA have negative prostate biopsies.
|
29808301 |
2018 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the data demonstrate that ONC201 downregulates the expression of key drivers of prostate cancer such as AR-V7 and downstream target genes including the clinically used biomarker PSA (KLK3).
|
29588330 |
2018 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Definitions of prostate-specific antigen (PSA) treatment response to RASND were defined as 6-week PSA <0.2 ng/mL (broad definition) or PSA <0.05 ng/mL (strict definition) in those who had undergone primary prostatectomy, and 6-week PSA level < post-radiotherapy nadir in those who had undergone primary radiotherapy.
|
28548372 |
2017 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adding PZ-ratio and MRI findings to the current predictive model (age, PSA density, percent-free PSA) significantly increased diagnostic accuracy in all patients (AUC: 0.871 vs. 0.812, p = 0.0059), but not in patient subgroup with PSA 4-10 ng/ml (AUC: 0.863 vs. 0.803, p = 0.12).
|
28422738 |
2017 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We extracted RNA from the initial biopsy and measured PCA3-shRNA2, PCA3 and PSA (qRT-PCR).
|
28380027 |
2017 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, men with higher iPSA are more likely to have a pre-RT PSA greater than 0.5 ng ml(-1) in response to neoadjuvant ADT and are therefore candidates for clinical trials testing newer, more aggressive hormone-ablative therapies.
|
23939133 |
2013 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aberrant expression of KLKs, presented in many human malignancies, highlights the significance of this gene family for early diagnosis, prognosis and monitoring of cancer patients, as it is strongly emphasized by the routine use of PSA (KLK3) for prostate cancer management.
|
20302518 |
2010 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA (hK3) is one of the human kallikreins, and is the most useful tumor marker for prostate cancer screening, diagnosis, prognosis and monitoring. hK2, another prostate-specific kallikrein, has also been proposed as a complementary prostate cancer biomarker.
|
15911097 |
2005 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, established RM11psa tumors ranging in size from 500 to 1,000 mm(3) were efficiently eliminated if Ad5-PSA priming was followed 7 days later by intratumoral injection of recombinant canarypox viruses (ALVAC) encoding interleukin-12 (IL-12), IL-2, and tumor necrosis factor-alpha.
|
11745487 |
2001 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As such, preoperative knowledge of f-PSA and c-PSA values and the three ratios provided no additional diagnostic information over standard PSA (t-PSA) values alone.
|
8753736 |
1996 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to compare the complete PSA mRNA gene sequences in benign and malignant prostate tissue to determine whether altered PSA phenotypes are a result of gene mutations and to compare the published PSA sequences.
|
8677566 |
1996 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that preoperative serum PSA level has significant predictive value in determining tumor burden and pathological stage, and this predictive value is increased by accounting for cancer and gland volume with PSA-cancer density.
|
7514689 |
1994 |